Literature DB >> 16775248

Doxycycline treatment for lymphangioleiomyomatosis with urinary monitoring for MMPs.

Marsha A Moses, Jay Harper, Judah Folkman.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16775248     DOI： 10.1056/NEJMc053410

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  44 in total

1.  Hereditary haemorrhagic telangiectasia: From symptomatic management to pathogenesis based treatment.

Authors:  Francisco José Fernández-Fernández
Journal:  Eur J Hum Genet       Date:  2009-11-04       Impact factor: 4.246

2.  Lymphangioleiomyomatosis: current and future.

Authors:  Maria Mavroudi; Paul Zarogoulidis; Nikolaos Katsikogiannis; Kosmas Tsakiridis; Haidong Huang; Antonios Sakkas; Anastasios Kallianos; Aggeliki Rapti; Eirini Sarika; Ilias Karapantzos; Konstantinos Zarogoulidis
Journal:  J Thorac Dis       Date:  2013-02       Impact factor: 2.895

3.  All vessels are not created equal.

Authors:  Diane R Bielenberg; Patricia A D'Amore
Journal:  Am J Pathol       Date:  2013-02-17       Impact factor: 4.307

Review 4.  Minireview: Lymphangioleiomyomatosis (LAM): The "Other" Steroid-Sensitive Cancer.

Authors:  Hen Prizant; Stephen R Hammes
Journal:  Endocrinology       Date:  2016-07-13       Impact factor: 4.736

5.  Surgical treatment of chylothorax caused by lymphangioleiomyomatosis.

Authors:  Mingliang Liu; Bingqun Wu; Yong Cui; Dong Chang; Shuhong Zhang; Min Gong
Journal:  J Thorac Dis       Date:  2014-02       Impact factor: 2.895

6.  Official American Thoracic Society/Japanese Respiratory Society Clinical Practice Guidelines: Lymphangioleiomyomatosis Diagnosis and Management.

Authors:  Francis X McCormack; Nishant Gupta; Geraldine R Finlay; Lisa R Young; Angelo M Taveira-DaSilva; Connie G Glasgow; Wendy K Steagall; Simon R Johnson; Steven A Sahn; Jay H Ryu; Charlie Strange; Kuniaki Seyama; Eugene J Sullivan; Robert M Kotloff; Gregory P Downey; Jeffrey T Chapman; MeiLan K Han; Jeanine M D'Armiento; Yoshikazu Inoue; Elizabeth P Henske; John J Bissler; Thomas V Colby; Brent W Kinder; Kathryn A Wikenheiser-Brokamp; Kevin K Brown; Jean F Cordier; Cristopher Meyer; Vincent Cottin; Jan L Brozek; Karen Smith; Kevin C Wilson; Joel Moss
Journal:  Am J Respir Crit Care Med       Date:  2016-09-15       Impact factor: 21.405

7.  A Model of Lymphangioleiomyomatosis in a Three-Dimensional Culture System.

Authors:  Toshio Kumasaka; Yoshito Hoshika; Etsuko Kobayashi; Keiko Mitani; Makiko K Okura; Young Kwon Hong; Kazuhisa Takahashi; Kuniaki Seyama
Journal:  Lymphat Res Biol       Date:  2015-11-17       Impact factor: 2.589

8.  Faslodex inhibits estradiol-induced extracellular matrix dynamics and lung metastasis in a model of lymphangioleiomyomatosis.

Authors:  Chenggang Li; Xiaobo Zhou; Yang Sun; Erik Zhang; John D Mancini; Andrey Parkhitko; Tasha A Morrison; Edwin K Silverman; Elizabeth P Henske; Jane J Yu
Journal:  Am J Respir Cell Mol Biol       Date:  2013-07       Impact factor: 6.914

9.  Broad-spectrum matrix metalloproteinase inhibition curbs inflammation and liver injury but aggravates experimental liver fibrosis in mice.

Authors:  Vincent E de Meijer; Deanna Y Sverdlov; Yury Popov; Hau D Le; Jonathan A Meisel; Vânia Nosé; Detlef Schuppan; Mark Puder
Journal:  PLoS One       Date:  2010-06-25       Impact factor: 3.240

10.  Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.

Authors:  Nancy Lee; Chelsey L Woodrum; Alison M Nobil; Aubrey E Rauktys; Michael P Messina; Sandra L Dabora
Journal:  BMC Pharmacol       Date:  2009-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.